Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (OTCPK:AZNCF)

AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

Business Wire November 21, 2014

MedImmune Presents Promising New Data in Systemic Lupus at American College of Rheumatology Meeting

Business Wire November 17, 2014

MedImmune Presents Positive Phase IIb Data for Mavrilimumab in Rheumatoid Arthritis at ACR Annual Meeting

Business Wire November 17, 2014

AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting

Business Wire November 16, 2014

Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer

Accesswire November 13, 2014

AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent

Business Wire November 13, 2014

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

PR Newswire November 11, 2014

U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes

Business Wire October 30, 2014

Duke Nuclear Integrates Learning and Compliance into Corporate Culture with SumTotal Talent Expansion Applications

Business Wire October 23, 2014

Brandon Hall Honors SumTotal Customers Praxair and McAfee with Talent and Learning Excellence Awards

Business Wire October 21, 2014

AstraZeneca Launches Fit2Me(TM), a Free Customized Diet and Lifestyle Support Program for People with Type 2 Diabetes

Business Wire October 15, 2014

BRILINTA Preferred Over Clopidogrel in 2014 AHA/ACC Guideline for the Management of Non-ST-Elevation Acute Coronary Syndromes

Business Wire October 6, 2014

FDA Approves MOVANTIK(TM) (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain

Business Wire September 16, 2014

Actor James Van Der Beek and AstraZeneca Join Forces to Educate Families about Influenza

PR Newswire September 15, 2014

BYDUREON® Pen, a Treatment Option for Adults with Type 2 Diabetes, Now Available in Pharmacies

Business Wire September 8, 2014

SumTotal Announces Results for First Half of 2014; Achieves 89 Percent Growth in New Customer Cloud Bookings

Business Wire September 3, 2014

US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA

Business Wire August 19, 2014

Immuno-Oncology Game-Changers from Big Pharma and Small Biotechs

Equities.com June 30, 2014

Investing in the Best Canadian Biotech Stocks

Equities.com June 23, 2014

Data Published In The New England Journal Of Medicine Demonstrate Naloxegol Improved Opioid-Induced Constipation In Chronic Pain Patients

PR Newswire June 19, 2014